ERCC2 and colorectal carcinoma: Boige et al. (European ancestry; France) found a significant association of the T allele of the ERCC2 rs1799787 SNP (c.1832-70C>T, intronic) with a decreased response to capecitabine/RT or CAPOX/RT neoadjuvant treatment in 316 CRC patients (stages II–III) (OR = 0.55; 95% CI = 0.33–0.93; p = 0.027 for CT/TT vs. CC) [29].